Vendeur : Ria Christie Collections, Uxbridge, Royaume-Uni
EUR 164,11
Quantité disponible : Plus de 20 disponibles
Ajouter au panierEtat : New. In.
Vendeur : Ria Christie Collections, Uxbridge, Royaume-Uni
EUR 164,11
Quantité disponible : Plus de 20 disponibles
Ajouter au panierEtat : New. In.
Vendeur : GreatBookPricesUK, Woodford Green, Royaume-Uni
EUR 164,09
Quantité disponible : 1 disponible(s)
Ajouter au panierEtat : New.
Vendeur : GreatBookPrices, Columbia, MD, Etats-Unis
EUR 180,91
Quantité disponible : Plus de 20 disponibles
Ajouter au panierEtat : New.
Vendeur : GreatBookPrices, Columbia, MD, Etats-Unis
EUR 181,15
Quantité disponible : 1 disponible(s)
Ajouter au panierEtat : As New. Unread book in perfect condition.
Vendeur : GreatBookPricesUK, Woodford Green, Royaume-Uni
EUR 164,09
Quantité disponible : Plus de 20 disponibles
Ajouter au panierEtat : New.
Vendeur : GreatBookPrices, Columbia, MD, Etats-Unis
EUR 182,64
Quantité disponible : 1 disponible(s)
Ajouter au panierEtat : New.
Langue: anglais
Edité par Springer Berlin Heidelberg, 2014
ISBN 10 : 3642445802 ISBN 13 : 9783642445804
Vendeur : moluna, Greven, Allemagne
EUR 136,16
Quantité disponible : Plus de 20 disponibles
Ajouter au panierEtat : New.
Langue: anglais
Edité par Springer Berlin Heidelberg, 2012
ISBN 10 : 3642282954 ISBN 13 : 9783642282959
Vendeur : moluna, Greven, Allemagne
EUR 136,16
Quantité disponible : Plus de 20 disponibles
Ajouter au panierGebunden. Etat : New.
Vendeur : GreatBookPricesUK, Woodford Green, Royaume-Uni
EUR 181,32
Quantité disponible : 1 disponible(s)
Ajouter au panierEtat : As New. Unread book in perfect condition.
Vendeur : Books Puddle, New York, NY, Etats-Unis
EUR 201,41
Quantité disponible : 4 disponible(s)
Ajouter au panierEtat : New. pp. 246.
Vendeur : Books Puddle, New York, NY, Etats-Unis
EUR 211,82
Quantité disponible : 4 disponible(s)
Ajouter au panierEtat : New. pp. 246 Index.
Vendeur : preigu, Osnabrück, Allemagne
EUR 140
Quantité disponible : 5 disponible(s)
Ajouter au panierTaschenbuch. Etat : Neu. Therapeutic Kinase Inhibitors | Ingo K. Mellinghoff (u. a.) | Taschenbuch | Current Topics in Microbiology and Immunology | x | Englisch | 2014 | Springer | EAN 9783642445804 | Verantwortliche Person für die EU: Springer Verlag GmbH, Tiergartenstr. 17, 69121 Heidelberg, juergen[dot]hartmann[at]springer[dot]com | Anbieter: preigu.
Langue: anglais
Edité par Springer Berlin Heidelberg, 2014
ISBN 10 : 3642445802 ISBN 13 : 9783642445804
Vendeur : AHA-BUCH GmbH, Einbeck, Allemagne
EUR 160,49
Quantité disponible : 1 disponible(s)
Ajouter au panierTaschenbuch. Etat : Neu. Druck auf Anfrage Neuware - Printed after ordering - Cancer drug development is currently undergoing a profound shift. Drugs targeting fundamental cellular processes such DNA-replication and microtubule function, often referred to as 'chemotherapy' and still the backbone of most cancer treatment regimens, are increasingly being complemented by or replaced with kinase inhibitors. This new class of drugs targets enzymes which provide growth and survival signals to cancer cells by transferring phosphate groups from Adenosine-5'-triphosphate (ATP) to other proteins, lipids, nucleotides, and carbohydrates. This book summarizes the current state of kinase inhibitor therapy for cancer. Successful drug development relies on the expertise and dedication of many experts. To reflect this team approach to finding new kinase inhibitors and defining their optimal use for cancer treatment, the editors invited experts in academia and pharmaceutical industry to share their insights into various aspects of this process, ranging from the first chemical screens, to preclinical testing and disease-focused clinical drug development. The editors and authors hope these lessons will be instructive for the novice as well as the expert.
Langue: anglais
Edité par Springer Berlin Heidelberg, Springer Berlin Heidelberg, 2012
ISBN 10 : 3642282954 ISBN 13 : 9783642282959
Vendeur : AHA-BUCH GmbH, Einbeck, Allemagne
EUR 160,49
Quantité disponible : 1 disponible(s)
Ajouter au panierBuch. Etat : Neu. Druck auf Anfrage Neuware - Printed after ordering - Cancer drug development is currently undergoing a profound shift. Drugs targeting fundamental cellular processes such DNA-replication and microtubule function, often referred to as 'chemotherapy' and still the backbone of most cancer treatment regimens, are increasingly being complemented by or replaced with kinase inhibitors. This new class of drugs targets enzymes which provide growth and survival signals to cancer cells by transferring phosphate groups from Adenosine-5'-triphosphate (ATP) to other proteins, lipids, nucleotides, and carbohydrates. This book summarizes the current state of kinase inhibitor therapy for cancer. Successful drug development relies on the expertise and dedication of many experts. To reflect this team approach to finding new kinase inhibitors and defining their optimal use for cancer treatment, the editors invited experts in academia and pharmaceutical industry to share their insights into various aspects of this process, ranging from the first chemical screens, to preclinical testing and disease-focused clinical drug development. The editors and authors hope these lessons will be instructive for the novice as well as the expert.
Vendeur : Buchpark, Trebbin, Allemagne
EUR 124,20
Quantité disponible : 1 disponible(s)
Ajouter au panierEtat : Sehr gut. Zustand: Sehr gut | Sprache: Englisch | Produktart: Bücher | Cancer drug development is currently undergoing a profound shift. Drugs targeting fundamental cellular processes such DNA-replication and microtubule function, often referred to as ¿chemotherapy¿ and still the backbone of most cancer treatment regimens, are increasingly being complemented by or replaced with kinase inhibitors. This new class of drugs targets enzymes which provide growth and survival signals to cancer cells by transferring phosphate groups from Adenosine-5'-triphosphate (ATP) to other proteins, lipids, nucleotides, and carbohydrates. This book summarizes the current state of kinase inhibitor therapy for cancer. Successful drug development relies on the expertise and dedication of many experts. To reflect this team approach to finding new kinase inhibitors and defining their optimal use for cancer treatment, the editors invited experts in academia and pharmaceutical industry to share their insights into various aspects of this process, ranging from the first chemical screens, to preclinical testing and disease-focused clinical drug development. The editors and authors hope these lessons will be instructive for the novice as well as the expert.
Vendeur : Revaluation Books, Exeter, Royaume-Uni
EUR 232,58
Quantité disponible : 2 disponible(s)
Ajouter au panierPaperback. Etat : Brand New. reprint edition. 234 pages. 8.75x6.00x0.50 inches. In Stock.
Vendeur : Revaluation Books, Exeter, Royaume-Uni
EUR 234,05
Quantité disponible : 2 disponible(s)
Ajouter au panierHardcover. Etat : Brand New. 2012 edition. 244 pages. 9.25x6.25x0.75 inches. In Stock.
Vendeur : GreatBookPricesUK, Woodford Green, Royaume-Uni
EUR 267,86
Quantité disponible : Plus de 20 disponibles
Ajouter au panierEtat : As New. Unread book in perfect condition.
Vendeur : Mispah books, Redhill, SURRE, Royaume-Uni
EUR 258,35
Quantité disponible : 1 disponible(s)
Ajouter au panierHardcover. Etat : Like New. LIKE NEW. SHIPS FROM MULTIPLE LOCATIONS. book.
Vendeur : GreatBookPrices, Columbia, MD, Etats-Unis
EUR 293,49
Quantité disponible : Plus de 20 disponibles
Ajouter au panierEtat : As New. Unread book in perfect condition.
Vendeur : Brook Bookstore On Demand, Napoli, NA, Italie
EUR 126,26
Quantité disponible : Plus de 20 disponibles
Ajouter au panierEtat : new. Questo è un articolo print on demand.
Vendeur : Brook Bookstore On Demand, Napoli, NA, Italie
EUR 126,26
Quantité disponible : Plus de 20 disponibles
Ajouter au panierEtat : new. Questo è un articolo print on demand.
Langue: anglais
Edité par Springer Berlin Heidelberg Apr 2014, 2014
ISBN 10 : 3642445802 ISBN 13 : 9783642445804
Vendeur : BuchWeltWeit Ludwig Meier e.K., Bergisch Gladbach, Allemagne
EUR 160,49
Quantité disponible : 2 disponible(s)
Ajouter au panierTaschenbuch. Etat : Neu. This item is printed on demand - it takes 3-4 days longer - Neuware -Cancer drug development is currently undergoing a profound shift. Drugs targeting fundamental cellular processes such DNA-replication and microtubule function, often referred to as 'chemotherapy' and still the backbone of most cancer treatment regimens, are increasingly being complemented by or replaced with kinase inhibitors. This new class of drugs targets enzymes which provide growth and survival signals to cancer cells by transferring phosphate groups from Adenosine-5'-triphosphate (ATP) to other proteins, lipids, nucleotides, and carbohydrates. This book summarizes the current state of kinase inhibitor therapy for cancer. Successful drug development relies on the expertise and dedication of many experts. To reflect this team approach to finding new kinase inhibitors and defining their optimal use for cancer treatment, the editors invited experts in academia and pharmaceutical industry to share their insights into various aspects of this process, ranging from the first chemical screens, to preclinical testing and disease-focused clinical drug development. The editors and authors hope these lessons will be instructive for the novice as well as the expert. 244 pp. Englisch.
Langue: anglais
Edité par Springer Berlin Heidelberg Mrz 2012, 2012
ISBN 10 : 3642282954 ISBN 13 : 9783642282959
Vendeur : BuchWeltWeit Ludwig Meier e.K., Bergisch Gladbach, Allemagne
EUR 160,49
Quantité disponible : 2 disponible(s)
Ajouter au panierBuch. Etat : Neu. This item is printed on demand - it takes 3-4 days longer - Neuware -Cancer drug development is currently undergoing a profound shift. Drugs targeting fundamental cellular processes such DNA-replication and microtubule function, often referred to as 'chemotherapy' and still the backbone of most cancer treatment regimens, are increasingly being complemented by or replaced with kinase inhibitors. This new class of drugs targets enzymes which provide growth and survival signals to cancer cells by transferring phosphate groups from Adenosine-5'-triphosphate (ATP) to other proteins, lipids, nucleotides, and carbohydrates. This book summarizes the current state of kinase inhibitor therapy for cancer. Successful drug development relies on the expertise and dedication of many experts. To reflect this team approach to finding new kinase inhibitors and defining their optimal use for cancer treatment, the editors invited experts in academia and pharmaceutical industry to share their insights into various aspects of this process, ranging from the first chemical screens, to preclinical testing and disease-focused clinical drug development. The editors and authors hope these lessons will be instructive for the novice as well as the expert. 244 pp. Englisch.
Vendeur : Majestic Books, Hounslow, Royaume-Uni
EUR 211,76
Quantité disponible : 4 disponible(s)
Ajouter au panierEtat : New. Print on Demand pp. 246 30 Illus. (21 Col.).
Langue: anglais
Edité par Springer Berlin Heidelberg, Springer Berlin Heidelberg Mär 2012, 2012
ISBN 10 : 3642282954 ISBN 13 : 9783642282959
Vendeur : buchversandmimpf2000, Emtmannsberg, BAYE, Allemagne
EUR 160,49
Quantité disponible : 1 disponible(s)
Ajouter au panierBuch. Etat : Neu. This item is printed on demand - Print on Demand Titel. Neuware -Cancer drug development is currently undergoing a profound shift. Drugs targeting fundamental cellular processes such DNA-replication and microtubule function, often referred to as ¿chemotherapy¿ and still the backbone of most cancer treatment regimens, are increasingly being complemented by or replaced with kinase inhibitors. This new class of drugs targets enzymes which provide growth and survival signals to cancer cells by transferring phosphate groups from Adenosine-5'-triphosphate (ATP) to other proteins, lipids, nucleotides, and carbohydrates.This book summarizes the current state of kinase inhibitor therapy for cancer. Successful drug development relies on the expertise and dedication of many experts. To reflect this team approach to finding new kinase inhibitors and defining their optimal use for cancer treatment, the editorsinvited experts in academia and pharmaceutical industry to share their insights into various aspects of this process, ranging from the first chemical screens, to preclinical testing and disease-focused clinical drug development. The editors and authorshope these lessons will be instructive for the novice as well as the expert.Springer-Verlag GmbH, Tiergartenstr. 17, 69121 Heidelberg 244 pp. Englisch.
Langue: anglais
Edité par Springer Berlin Heidelberg, Springer Berlin Heidelberg Apr 2014, 2014
ISBN 10 : 3642445802 ISBN 13 : 9783642445804
Vendeur : buchversandmimpf2000, Emtmannsberg, BAYE, Allemagne
EUR 160,49
Quantité disponible : 1 disponible(s)
Ajouter au panierTaschenbuch. Etat : Neu. This item is printed on demand - Print on Demand Titel. Neuware -Cancer drug development is currently undergoing a profound shift. Drugs targeting fundamental cellular processes such DNA-replication and microtubule function, often referred to as ¿chemotherapy¿ and still the backbone of most cancer treatment regimens, are increasingly being complemented by or replaced with kinase inhibitors. This new class of drugs targets enzymes which provide growth and survival signals to cancer cells by transferring phosphate groups from Adenosine-5'-triphosphate (ATP) to other proteins, lipids, nucleotides, and carbohydrates. This book summarizes the current state of kinase inhibitor therapy for cancer. Successful drug development relies on the expertise and dedication of many experts. To reflect this team approach to finding new kinase inhibitors and defining their optimal use for cancer treatment, the editorsinvited experts in academia and pharmaceutical industry to share their insights into various aspects of this process, ranging from the first chemical screens, to preclinical testing and disease-focused clinical drug development. The editors and authorshope these lessons will be instructive for the novice as well as the expert.Springer Verlag GmbH, Tiergartenstr. 17, 69121 Heidelberg 244 pp. Englisch.
Vendeur : Majestic Books, Hounslow, Royaume-Uni
EUR 222,40
Quantité disponible : 4 disponible(s)
Ajouter au panierEtat : New. Print on Demand pp. 246 30 Illus. (21 Col.).
Vendeur : Biblios, Frankfurt am main, HESSE, Allemagne
EUR 213,13
Quantité disponible : 4 disponible(s)
Ajouter au panierEtat : New. PRINT ON DEMAND pp. 246.